An official website of the United States government
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Trial Status: active
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for
participants with solid tumors that are expressing a protein called nectin-4.
The main questions it aims to answer are:
What is the the safe and effective dose of CRB-701 when used alone? What cancers can be
treated effectively with CRB-701?
Participants will be asked to attend clinic and be given a intravenous infusion of
CRB-701 on its own. They will have blood tests and other assessments to measure whether
CRB-701 will have CT or MRI scans to measure the effect on tumors.
Inclusion Criteria
Confirmed diagnosis of select advanced or metastatic nectin-4 expressing solid tumors that have progressed following at least one line of therapy or have no other standard therapy with proven clinical benefit.
Exclusion Criteria
Active of uncontrolled CNS metastases
History of solid tumors other than the diseases under study
History of and/or current cardiovascular events or conditions in the previous 6 months
